Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04409795 · ClinicalTrials.gov registry record · Phase 2
Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study
A Phase 2 study, sponsored by Joslin Diabetes Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04409795: Completed Phase 2 study, sponsored by Joslin Diabetes Center.
NCT04409795 is a Phase 2 study that has completed, run by Joslin Diabetes Center. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04409795, a Phase 2 study, has completed, sponsored by Joslin Diabetes Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of adding oral hypoglycemic agents (OHA) to existing insulin treatment in monogenic variant carriers of the Joslin 50-Year Medalist Study ("Medalists"), who are characterized by ≥50 years of insulin-dependent diabetes. Our primary objective is to evaluate whether the presence of human leukocyte antigen (HLA) high-risk alleles for diabetes (DR3 and/or DR4) can affect the effectiveness of OHA in these subjects.
Primary Outcome
Change in HbA1c (%) between the two study groups
Interventions
- DRUG Sitagliptin
- DRUG Metformin Extended Release Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-08-26 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 2 |
What the finished NCT04409795 record still lists
NCT04409795 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Sitagliptin is the first listed.
NCT04409795 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04409795 about?
NCT04409795 is a clinical study titled "Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study". The purpose of this study is to evaluate the efficacy of adding oral hypoglycemic agents (OHA) to existing insulin treatment in monogenic variant carriers of the Joslin 50-Year Medalist Study ("Medalists"), who are characterized by ≥50 years of insulin-dependent diabetes. Our primary objective is to...
What is the current status of trial NCT04409795?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2021-08-26. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT04409795?
The interventions under investigation include: Sitagliptin (DRUG), Metformin Extended Release Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT04409795?
This trial is sponsored by Joslin Diabetes Center, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04409795's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI